Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 08, 2020 | May 11, 2020 |
| GLAUKOS CorpGKOS · Entity 3510 | Director | June 03, 2021 | June 07, 2021 |
| LENSAR, Inc.LNSR · Entity 6733 | Director | June 03, 2026 | June 05, 2026 |
| Oyster Point Pharma, Inc.OYST · Entity 15903 | Director | January 05, 2022 | January 07, 2022 |
| RxSight, Inc.RXST · Entity 1226 | Director | June 17, 2026 | June 18, 2026 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director | September 15, 2026 | September 17, 2026 |
| Vivani Medical, Inc.EYES · Entity 6636 | Director | June 04, 2019 | June 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 08, 2020 · Filed May 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,349 |
Ending reported balance
After 2020-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-08 · Grant · Acquired 1,101 · Balance 11,004 F1: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Row 2 · 2020-05-08 · Grant · Acquired 345 · Balance 11,349 F2: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. |
| Common StockSEC Table I · non-derivative | IndirectLink Family Enterprise, LP | 4,722 |
Reported balance
Holding disclosure · report date 2020-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,722 |
| Common StockSEC Table I · non-derivative | IndirectLink Family Trust | 6,050 |
Reported balance
Holding disclosure · report date 2020-05-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 6,050 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.
F2: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.
GLAUKOS Corp
Report date June 03, 2021 · Filed June 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,821 |
Reported balance
After 2021-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 2,382 · Balance 17,821 F1: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2: Includes 2,382 restricted stock units that have not yet vested or been delivered to the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 40,479 |
Reported balance
Holding disclosure · report date 2021-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 40,479 F3: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.
F2: Includes 2,382 restricted stock units that have not yet vested or been delivered to the Reporting Person.
F3: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein.
LENSAR, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 568,062 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,421 · Balance 568,062 F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
Oyster Point Pharma, Inc.
Report date January 05, 2022 · Filed January 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Limited Partnership | 33,480 |
Reported balance
After 2022-01-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-01-05 · Other · Acquired 6,438 · Balance 33,480 F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV. F2: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,074 |
Reported balance
After 2022-01-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-01-05 · Other · Acquired 401 · Balance 2,074 F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to The Link Family Trust, dated May 19, 2005, without consideration. F4: Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 27,942 |
Reported balance
Holding disclosure · report date 2022-01-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 27,942 F5: Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC. |
| Common StockSEC Table I · non-derivative | Direct | 10,066 |
Reported balance
Holding disclosure · report date 2022-01-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 10,066 |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,465 |
Reported balance
Holding disclosure · report date 2022-01-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,465 F6: Shares held by Versant Side Fund IV following its distribution to the Reporting Person reported herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Versant Side Fund IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant Side Fund IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 414,607 |
Reported balance
Holding disclosure · report date 2022-01-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 414,607 F7: Shares held by Capital IV following its distribution to the Reporting Person herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Capital IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Capital IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV.
F2: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to The Link Family Trust, dated May 19, 2005, without consideration.
F4: Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust.
F5: Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC.
F6: Shares held by Versant Side Fund IV following its distribution to the Reporting Person reported herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Versant Side Fund IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant Side Fund IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F7: Shares held by Capital IV following its distribution to the Reporting Person herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Capital IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Capital IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
RxSight, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 74,892 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 37,037 · Balance 74,892 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 21,248 |
Reported balance
Holding disclosure · report date 2026-06-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 21,248 F3: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.
F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
F3: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein.
Tarsus Pharmaceuticals, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,487 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 201 · Balance 106,987 F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Row 2 · 2026-09-15 · Sale · Disposed 11,675 · Balance 95,312 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F3: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-09-15 · Sale · Disposed 759 · Balance 94,553 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-09-15 · Sale · Disposed 66 · Balance 94,487 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 605 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 201 · Balance 605 F5: Each RSU represents a contingent right to receive one share of the Company's common stock. F6: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
F3: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: Each RSU represents a contingent right to receive one share of the Company's common stock.
F6: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Vivani Medical, Inc.
Report date June 04, 2019 · Filed June 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-06-04 | Direct | 56,685 |
Reported balance
After 2019-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-04 · Grant · Acquired 56,685 · Balance 56,685 F1: The stock options have a 10-year term and fully vest on the earlier of annual grant date anniversary or the date of the next annual shareholder's meeting. F2: Awarded as compensation for serving on the Board of Directors and its committees. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a 10-year term and fully vest on the earlier of annual grant date anniversary or the date of the next annual shareholder's meeting.
F2: Awarded as compensation for serving on the Board of Directors and its committees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001228684-26-000010 · wk-form4_1789676560.xml · derivative · entry 5 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605 Underlying: Common Stock · 201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. F6 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 66 | $80.01 | $5,280.66 |
DisclosureSEC source: 0001228684-26-000010 · wk-form4_1789676560.xml · nonDerivative · entry 4 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,487 F2 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 759 | $79.00 | $59,961.00 |
DisclosureSEC source: 0001228684-26-000010 · wk-form4_1789676560.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,553 F2 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 11,675 | $78.33 | $914,502.75 |
DisclosureSEC source: 0001228684-26-000010 · wk-form4_1789676560.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,312 F2 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001228684-26-000010 · wk-form4_1789676560.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 806 | $0.00 | $0.00 |
DisclosureSEC source: 0001228684-26-000008 · wk-form4_1782765039.xml · derivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 806 Underlying: Common Stock · 806 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. F4 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001228684-26-000008 · wk-form4_1782765039.xml · derivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,417 Underlying: Common Stock · 2,417 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 3,837 | $0.00 Strike: $64.34 | $0.00 |
DisclosureSEC source: 0001228684-26-000008 · wk-form4_1782765039.xml · derivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,837 Underlying: Common Stock · 3,837 shares Expires 2036-06-24 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:08 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 37,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-275841 · ownership.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,892 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,928 | $62.94 | $121,348.32 |
DisclosureSEC source: 0001228684-26-000006 · wk-form4_1781727420.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,786 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $62.68 to $63.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 10,572 | $61.97 | $655,146.84 |
DisclosureSEC source: 0001228684-26-000006 · wk-form4_1781727420.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,714 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $61.67 to $62.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 2,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001228684-26-000004 · wk-form4_1781640385.xml · derivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 2,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001228684-26-000004 · wk-form4_1781640385.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:30 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 17,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-259985 · ownership.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 568,062 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 493 | $69.75 | $34,386.75 |
DisclosureSEC source: 0001228684-26-000002 · wk-form4_1773864674.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,332 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $69.68 to $69.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,378 | $69.03 | $578,333.34 |
DisclosureSEC source: 0001228684-26-000002 · wk-form4_1773864674.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,825 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $68.64 to $69.63. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,629 | $68.09 | $247,098.61 |
DisclosureSEC source: 0001228684-26-000002 · wk-form4_1773864674.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,203 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $67.60 to $68.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:07 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,766 | $81.50 | $388,429.00 |
DisclosureSEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 5 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Link Family Enterprise, LP Disclosed balance after: 0 F5 · kind: The sales were not effected by a sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.21 to $81.79. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:07 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,680 | $80.71 | $458,432.80 |
DisclosureSEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 4 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Link Family Enterprise, LP Disclosed balance after: 4,766 F5 · kind: The sales were not effected by a sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.21 to $81.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:07 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,148 | $82.39 | $94,583.72 |
DisclosureSEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,832 F1 · kind: The sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.23 to $82.92. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:07 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 6,306 | $81.75 | $515,515.50 |
DisclosureSEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,980 F1 · kind: The sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.21 to $82.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:07 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,046 | $80.80 | $407,716.80 |
DisclosureSEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,286 F1 · kind: The sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.21 to $81.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 21:00 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001228684-25-000003 · wk-form4_1758229231.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,332 Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 21:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 27,116 | $57.00 | $1,545,612.00 |
DisclosureSEC source: 0001819790-25-000113 · wk-form4_1757538213.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,332 F1 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $56.66 to $57.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000088 · wk-form4_1750104194.xml · derivative · entry 5 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F6 · derivative.expiration_date: RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 3,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-25-000088 · wk-form4_1750104194.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000088 · wk-form4_1750104194.xml · derivative · entry 4 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,954 Underlying: Common Stock · 2,954 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F5 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 4,540 | $0.00 Strike: $40.95 | $0.00 |
DisclosureSEC source: 0001819790-25-000088 · wk-form4_1750104194.xml · derivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,540 Underlying: Common Stock · 4,540 shares Expires 2035-06-11 F3 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:38 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 10,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081963 · ownership.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,855 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 3, 2025. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| May 23, 2025 Filed May 28, 2025 20:30 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 7,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-078370 · ownership.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,641 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 23, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:34 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,021 | $26.53 | $133,207.13 |
DisclosureSEC source: 0000950170-24-097097 · ownership.xml · nonDerivative · entry 5 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Flying L Partners XI, LLC Disclosed balance after: 0 F5 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.42 to $26.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held directly held by Flying L Partners XI, LLC. The Reporting Person is the manager of Flying L Partners XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:34 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 29,979 | $26.01 | $779,753.79 |
DisclosureSEC source: 0000950170-24-097097 · ownership.xml · nonDerivative · entry 4 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Flying L Partners XI, LLC Disclosed balance after: 5,021 F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.42 to $26.41. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held directly held by Flying L Partners XI, LLC. The Reporting Person is the manager of Flying L Partners XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:34 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | OtherCommon Stock | 27,116 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097097 · ownership.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,098 F1 · kind: Represents an in-kind pro-rata distribution, and not a purchase or sale, without additional consideration by Flying L Partners XI, LLC to its partners. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:34 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | OtherCommon Stock | 10,446 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097097 · ownership.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Link Family Enterprise, LP Disclosed balance after: 10,446 F1 · kind: Represents an in-kind pro-rata distribution, and not a purchase or sale, without additional consideration by Flying L Partners XI, LLC to its partners. F3 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:34 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | OtherCommon Stock | 74,892 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097097 · ownership.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Flying L Partners XI, LLC Disclosed balance after: 35,000 F1 · kind: Represents an in-kind pro-rata distribution, and not a purchase or sale, without additional consideration by Flying L Partners XI, LLC to its partners. F2 · ownership.nature: The shares are held directly held by Flying L Partners XI, LLC. The Reporting Person is the manager of Flying L Partners XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 22:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000102 · wk-form4_1719354324.xml · derivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 22:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 3,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000102 · wk-form4_1719354324.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:28 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000073 · wk-form4_1718400524.xml · derivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:28 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $33.14 | $0.00 |
DisclosureSEC source: 0001819790-24-000073 · wk-form4_1718400524.xml · derivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:17 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 2,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-071313 · ownership.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,103 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 6, 2024. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:30 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-057102 · ownership.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,267 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 7, 2025, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:49 UTC | RxSight, Inc. RXST · Entity 1226 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-010569 · ownership.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 21,248 F2 · ownership.nature: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:49 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 7,652 | $50.01 | $382,664.28 |
DisclosureSEC source: 0000950170-24-010569 · ownership.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 24,248 F3 · price: Represents the weighted average share price of an aggregate total of 7,652 shares sold in the price range of $49.91 to $50.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:49 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 20,598 | $49.54 | $1,020,455.82 |
DisclosureSEC source: 0000950170-24-010569 · ownership.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 31,900 F1 · price: Represents the weighted average share price of an aggregate total of 20,598 shares sold in the price range of $48.91 to $49.90 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:46 UTC | RxSight, Inc. RXST · Entity 1226 | OtherCommon Stock | 21,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046645 · doc4.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 52,498 F1 · shares: Represents a distribution not for value of shares of the Issuer's Common Stock to the members of Flying L Partners, II LLC on a pro rata basis based upon each such member's respective capital interests in Flying L Partners, II LLC. The Reporting Person is a managing member of Flying L Partners, II LLC. F3 · ownership.nature: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:46 UTC | RxSight, Inc. RXST · Entity 1226 | OtherCommon Stock | 2,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046645 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,549 F1 · shares: Represents a distribution not for value of shares of the Issuer's Common Stock to the members of Flying L Partners, II LLC on a pro rata basis based upon each such member's respective capital interests in Flying L Partners, II LLC. The Reporting Person is a managing member of Flying L Partners, II LLC. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:46 UTC | RxSight, Inc. RXST · Entity 1226 | OtherCommon Stock | 694,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046645 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · shares: Represents a distribution not for value of shares of the Issuer's Common Stock to the members of Flying L Partners, II LLC on a pro rata basis based upon each such member's respective capital interests in Flying L Partners, II LLC. The Reporting Person is a managing member of Flying L Partners, II LLC. F2 · ownership.nature: Shares held by Flying L Partners, II LLC. The Reporting Person is a managing member of Flying L Partners, II LLC and may be deemed to share voting and investment power over the securities held by Flying L Partners, II LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 21:47 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000054 · wk-form4_1687816019.xml · derivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 21:47 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001819790-23-000054 · wk-form4_1687816019.xml · derivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000041 · wk-form4_1687385320.xml · derivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.